Calder’s RSV program has animal proof of principle and is ready for clinical manufacturing. Our universal influenza program has solved all major engineering hurdles and the vaccine will be ready for preclinical animal testing in Q4 of 2023, and our EBV discovery program is initiated.

Calder Pipeline